Demonstrating effectiveness in a post-placebo era

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 2, 2001, Pages 115-120

  Urquhart, John ^a,b,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b AARDEX Ltd/APREX Corp   (Netherlands)

^c FRCP(Edin)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; PLACEBO;

ACCURACY; ANALYTIC METHOD; DRUG DETERMINATION; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

CONTROLLED CLINICAL TRIALS; DRUG DESIGN; HUMANS; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 0034887810     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.117285     Document Type: Note

References (42)

1. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues
2. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases
3. Helsinki's new clinical rules: Fewer placebos, more disclosure
4. US company's plan for trial in Latin America draws fire
5. Beyond Helsinki: A vision for global health ethics
6. International Conference on Harmonisation; Choice of control group in clinical trials
7. ICH harmonised tripartite guideline: Choice of control group and related issues in clinical trials
8. Problems of compliance with drug treatment: New solutions?
9. The electronic medication event monitor - Lessons for pharmacotherapy
10. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens
11. The impact of compliance in pharmacokinetic studies
12. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
13. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions
14. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring
15. Patient compliance and therapeutic coverage: Comparison of amlodipine versus nifedipine (slow-release) in the treatment of hypertension
16. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension
17. Achieving and assessing therapeutic coverage
18. Analysis of electronic event monitored adherence
19. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients
20. Clinical trial prerandomization compliance (adherence) screen
21. The qualification period
22. Time to stop counting the tablets?
23. The natural history of medication compliance in a drug trial: Limitations of pill counts
24. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring
25. Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts
26. Antihypertensive medication-taking. Investigation of a simple regimen
27. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator
28. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice
29. Any questions
30. Improving patient adherence: State of the art, with a special focus on medication taking for cardiovascular disorders
31. Detection methods and strategies for improving medication compliance
32. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens
33. Medication compliance as a feature in drug development
34. Electronic measurement
35. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial
36. Assessment and reporting of clinical pharmacology information in drug labeling
37. One in five marketed drugs undergoes a dosage change: 1980-99
38. Predictors of long-term persistence on statins in a subsidized clinical population
39. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
40. Persistence with treatment for hypertension in actual practice
41. Effect of intial drug choice on persistence with antihypertensive therapy: The importance of actual practice data